Peptide self-aggregation and peptide complementarity as bases for the evolution of peptide receptors: A review

Journal of Molecular Recognition

Volumn 18, Issue 1, 2005, Pages 40-49

  Root Bernstein, Robert S ^a  

^a MICHIGAN STATE UNIVERSITY   (United States)

Author keywords

Binding; Buffering; Modular evolution; Molecular recognition theory; Peptides; Stereospecific; Structure function

Indexed keywords

PEPTIDE; RECEPTOR;

AMINO ACID SEQUENCE; ANIMAL; CHEMICAL MODEL; CHEMISTRY; CLASSIFICATION; GENETICS; HUMAN; MOLECULAR EVOLUTION; MOLECULAR GENETICS; PHYLOGENY; REVIEW; SEQUENCE HOMOLOGY;

AMINO ACID SEQUENCE; ANIMALS; EVOLUTION, MOLECULAR; HUMANS; MODELS, CHEMICAL; MOLECULAR SEQUENCE DATA; PEPTIDES; PHYLOGENY; RECEPTORS, PEPTIDE; SEQUENCE HOMOLOGY, AMINO ACID;

EID: 11244327566     PISSN: 09523499     EISSN: None     Source Type: Journal    
DOI: 10.1002/jmr.690     Document Type: Review

References (107)

1. Anzenbacher P, Kalous V. 1975. Binding of D-glucose to insulin. Biochim. Biophys. Acta 386: 603-607.
2. Biro J. 1983. Comparative analyses of specificity in protein-protein interactions. Part II. The complementarity coding of some proteins as a possible source of specificity in protein-protein interactions. Med. Hypoth. 7: 981-993.
3. Blalock JE. 1990. Complementarity of peptides specified by 'sense' and 'antisense' strands of DNA. Trends Biotechnol. 8: 140-144.
4. Blalock JE. 1995. Genetic origins of protein shape and interaction rules. Nat. Med. 1. 1222-1223.
5. Blalock JE, Bost KL. 1988. Ligand receptor characteristics of peptides encoded by complementary nucleic acids: implications for a molecular recognition code. Rec. Prog. Horm. Res. 44: 199-222.
6. Blalock JE, Smith EM. 1984. Hydropathic anti-complementarity of amino acids based on the genetic code. Biochem. Biophys. Res. Commun. 121: 203-207.
7. Borovsky D, Powell CA, Nayar JK, Blalock JE, Hayes TK. 1994. Characterization and localizatin of mosquito-gut receptors for trypsin modulating oostatic factor using a complementary peptide and immunocytochemistry. FASEB J. 8: 350-355.
8. Bost KL, Blalock JE. 1989. Complementary peptides as interactive sites for protein binding. Viral Immunol. 2: 229-238.
9. Bost KL, Smith EM, Blalock JE. 1985a. Similarity between the corticotropin (ACTH) receptor and a peptide encoded by an RNA that is complementary to ACTH mRNA. Proc. Natl Acad. Sci. USA 82: 1372-1375.
10. Bost KL, Smith EM, Blalock JE. 1985b. Regions of complementarity between the messenger RNAs for epidermal growth factor, transferring, interleukin-2 and their respective receptors. Biochem. Biophys. Res. Commun. 128: 1373-1380.
11. Breslow E. 1979. Chemistry and biology of the neurophysins. A. Rev. Biochem. 48: 251-274.
12. Cao C, Brown MR. 2001. Localization of an insulin-like peptide in brains of two flies. Cell Tissue Res. 304: 317-321.
13. Carr DJ, Bost KL, Blalock JE. 1986. An antibody to a peptide specified by an RNA that is complementary to gamma-endorphin mRNA recognizes an opiate receptor. J. Neuroimmunol. 12: 329-337.
14. Chaiken I. 1992. Interactions and uses of antisense peptides in affinity technology. J. Chromotogr. 597: 29-36.
15. Chaiken IM, Abercrombie DM, Kanmera T, Sequeira RP. 1983. Neuronal peptide-protein complexes: neurophysins and associated neuropeptide hormones. Pept. Protein Rev. 1: 139-209.
16. Chang X, Keller D, O'Donoghue SI, Led JJ. 2002. NMR studies of the aggregation of glucagon-like peptide-1: formation of a symmetric helical dimer. FEBS Lett. 151: 165-170.
17. Chow BK, Yuen TT, Chan KW. 1997. Molecular evolution of vertebrate VIP receptors and functional characterization of a VIP receptor from goldfish Carassius auratus. Gen. Comp. Endocrinol. 105: 176-185.
18. Clarke BL, Blalock JE. 1990. Steroidogenic activity of a peptide specified by the reversed sequence of corticotropin mRNA. Proc. Natl Acad. Sci. USA 87: 9708-9711.
19. Conlon JM. 2001. Evolution of the insulin molecule: insights into structure-activity and phylogenetic relationships. Peptides 22: 1183-1193.
20. Cox JA, Comte M, Fitton JE, DeGrado WF. 1985. The interaction of calmodulin with amphiphilic peptides. J. Biol. Chem. 260: 2527-2534.
21. Crick FHC. 1968. The origin of the genetic code. J. Mol. Biol. 38: 367-379.
22. Darlison MG, Richter D. 1999. The 'chicken and egg' problem of co-evolution of peptides and their cognate receptors: which came first? Results Probl. Cell Differ. 26: 1-11.
23. Davids JW, ElBakri A, Heal J, Christie G, Roberts GW, Rkaynes JG, Miller AD. 1997. Design of antisense (complementary) peptides as selective inhibitors of cytokin interleukin-1. Angew. Chem. 3: 962-967.
24. De Gasparo M, Whitebread S, Einsie K, Heusser C. 1989. Are the antibodies to a peptide complementary to angiotensin II useful to isolate the angiogensin II receptor? Biochem. J. 261: 310-311.
25. Dillon PF, Root-Bernstein RS. 2004. Molecular weight and binding energy dependence of electric field molecular delivery. Appl. Bionics Biomech. (in press).
26. Dorit RL, Riley MA. 2002. When comparative information leads us astray: the receptor-binding region of colicin E9. J. Mol. Evol. 55: 347-355.
27. Dwyer DS. 1989. Amino acid sequence homology between ligands and their receptors: potential identification of binding sites. Life Sci. 45: 421-429.
28. Dwyer DS. 1998. Assembly of exons from unitary transposable genetic elements: implications for the evolution of protein-protein interactions. J. Theor. Biol. 194: 11-27.
29. Eberle AN, Huber M. 1991. Antisense peptides: tools for receptor isolation. Lack of antisense MSH and ACTH to interact with their sense peptides and to induce receptor-specific antibodies. J. Recept. Res. 11: 13-43.
30. Elton S, Oparil S, Blalock JE. 1988. The use of complementary peptides in the purification of an angiotensin II binding protein. J. Hypertens. Suppl. 6(4): S404-S407.
31. Fryxell KJ, Meyerowitz EM. 1991. The evolution of rhodopsins and neurotransmitter receptors. J. Mol. Evol. 33: 367-378.
32. Goldstein A, Brutlag DL. 1989. Is there a relationship between DNA sequences encoding peptide ligands and their receptors? Proc. Natl Acad. Sci. USA 86: 42-45.
33. Graham GJ, Freshney MG, Donaldson D, Pragnell IB. 1992. Purification and biochemical characterization of human and murine stem cell inhibitors (SCI). Growth Factors 7: 151-160.
34. Graham GJ, MacKenzie J, Lowe S, Tsang ML, Weatherbee JA, Issacson A, Medicherla J, Fang F, Wilkinson PC, Prgnell IB. 1994. Aggregation of the chemokine MIP-1 alpha is a dynamic and reversible phenomenon. Biochem. Biol. Anal. J. Biol. Chem. 269: 4974-4978.
35. Heal JR, Bino S, Ray KP, Christie G, Miller AD, Raynes JG. 1999. A search within the IL-1 type I receptor reveals a peptide with hydropathic complementarity to the IL-1 beta trigger loop which binds to IL-1 and inhibits in vitro responses. Mol. Immunol. 36: 1141-1148.
36. Heal JR, Roberts GW, Christie G, Miller AD. 2002. Inhibition of beta-amyloid aggregation and neurotoxicity by complementary (antisense) peptides. Chembiochem 3: 86-92.
37. Herrera VL, Ruiz-Opazo N. 2001. Identification of a novel V1-type AVP receptor based on the molecular recognition theory. Mol. Med. 8: 499-506.
38. Hesch RD. 1991. Classification of cell receptors. Curr. Top. Pathol. 83: 13-51.
39. Hirose S, Hagiwara H, Takei Y. 2001. Comparative molecular biology of natriuretic peptide receptors. Can. J. Physiol. Pharmac. 79: 665-672.
40. Holsworth DD, Kiely JS, Root-Bernstein RS, Overhiser RW. 1994. Antisense-designed peptides: a comparative study focusing on possible complements to angiotensin II. Pept. Res. 7: 185-193.
41. Huang X, Miller W. 1991. A time-efficient, linear-space local similarity algorithm. Adv. Appl. Mate. 12: 337-357.
42. Ildis RG. 1980. The principle of cross-stereo-complementarity and the symmetry of the genetic code. Mendeleev Chemistry J. 25: 431-434.
43. Jurzak M, Pavo I, Fahrenholz F. 1993. Lack of interaction of vasopressin with its antisense peptides: a functional and immunological study. J. Recept. Res. 13: 881-902.
44. Kalous V, Anzenbacher P. 1979. Mechanism of the insulin-glucose interactions. Acta Diabetol. Lat. 16: 169-174.
45. Kelly JM, Trinder D, Phillips PA, Casley DJ, Kemp B, Mooser V, Johnston CI. 1990. Vasopressin antisense peptide interactions with the V1 receptor. Peptides 11: 857-862.
46. Kluczyk A, Cebrat M, Zbozien-Pacamaj R, Lisowski M, Stefanowicz P, Wieczorek Z, Siemion IZ. 2004. On the peptide-antipeptide interactions in interleukin-1 receptor system. Acta Biochem. Pol. 51: 57-66.
47. Krishnadas A, Onyuksel H, Rubinstein I. 2003. Interactions of VIP, secretin and PACAP(1-38) with phospholipids: a biological paradox revisited. Curr. Pharm. Des. 9: 1005-1012.
48. Kummer G, Keller R. 1993. High-affinity binding of crustacean hyperglycemic hormone (CHH) to hepatopancreatic plasma membranes of the crab Carcinus maenas and the crayfish Orconectes limosus. Peptides 14: 103-108.
49. Kyte J, Doolittle RF. 1982. A simple method for displaying the hydropathic character of a protein. J. Mol. Biol. 157: 105-132.
50. Lantz O, Bendelac A. 1994. An invariant T cell receptor alpha chain is used by a unique subset of major histocompatibility complex class I-specific CD4+ and CD4-*-T cells in mice and humans. J. Exp. Med. 180: 1097-1106.
51. Larhammar D. 1996. Evolution of neuropeptide Y, peptide YY and pancreatic polypeptide. Regul. Pept. 62: 1-11.
52. Larson N, Samuelsson T, Zwieb C. 1998. The signal recognition particle database. Nucl. Acids Res. 26: 177-178.
53. Lau SH, Rivier J, Vale W, Kaiser ET, Kezdy FJ. 1983. Surface properties of an amphiphilic peptide hormone and of its analog: corticotropin-relaesing faqctor and sauvagine. Proc. Natl Acad. Sci. USA 80: 7070-7074.
54. Lee PD, Giudice LC, Conover CA, Powell DR. 1997. Insulin-like growth factor binding protein-1: recent findings and new directions. Proc. Soc. Exp. Biol. Med. 216: 319-357.
55. Leibush BN, Lappova YL, Bondareva VM, Chistyacova OV, Gutierrez J, Plisetskaya EM. 1998. The insulin-family peptide-receptor interaction at the early stage of vertebraate evolution. Comp. Biochem. Physiol. B Biochem. Mol. Biol. 121: 57-63.
56. Lu FX, Alyar N, Chaiken I. 1991. Affinity capture of [Arg8]vasopressin- receptor complex using immobilized antisense peptide. Proc. Natl Acad.Sci. USA 88: 3642-3646.
57. Martin-Moe SA, Lehr R, Cauley MD, Moe GR. 1995. Hydrophobic interactions and the design of receptor mimetic peptides. Pept. Res. 8: 70-76.
58. McGuigan JE, Campbell-Thompson M. 1992. Complementary peptide to the carboxyl terminal tetrapeptide of gastrin. Gastroenterology 103: 749-758.
59. Mekler LB. 1969. Specific selective interaction between amino acid groups of polypeptide chains. Biofizika 14: 581-584.
60. Moyle WR, Campbell RK, Myers RV, Bernard MP, Han Y, Wang X. 1994. Co-evolution of ligand-receptor pairs. Nature 368: 251-255.
61. Mulcahey JJ, Neill JD, Dion LD, Bost KL, Blalock JE. 1986. Antibodies to the binding site of the receptor for luteinizing hormone-releasing hormone (LHRH): generation with a synthetic decapeptide encoded by an RNA complementary to LHRH mRNA. Proc. Natl Acad. Sci. USA 83: 9714-9718.
62. Mulchahey JJ, Nagy G, Neill JD. 1999. A molecular recognition hypothesis for nonpeptides: Na + K + ATPas and endogenous digitalis-like peptides. Cell Mol. Life. Sci. 55: 653-663.
63. Muller We, Skorokhod A, Muller IM. 1999. Receptor tyrosine kinase, an autopomorphic character of metazoa: identification in marine sponges. Acta Biol. Hung. 50: 395-411.
64. Navarro I, Leibush B, Moon TW, Plisetskaya EM, Banos N, Mendez E, Planas, JV, Gutierrez J. 1999. Insulin, insulin-like growth factor-I (IGF-I) and glucagon: the evolution of their receptors. Comp. Biochem. Physiol. B Biochem. Mol. Biol. 122: 1137-1153.
65. Orts RJ, Burot BC, Sartin JL. 1980. Inhibitory properties of a bovine pineal tripeptide, threonylseryllysine, on serum follicle-stimulating hormone. Neuroendocrinology 31: 92-95.
66. Park Y, Kim YJ, Adams ME. 2002. Identification of G protein-coupled receptors for Drosophila PRXamid peptides, CCAP, corazonin, and AKH supports a theory of ligand-receptor coevolution. Proc. Natl Acad. Sci. USA 99: 11423-11428.
67. Peterson A, Seed B. 1987. Monoclonal anatibody and ligand binding sites of the T cell erythrocyte receptor (CD2). Nature 329: 842-846.
68. Plisetskaya EM. 1998. Some of my not so favorite things about insulin and insulin-like growth factors in fish. Comp. Biochem. Physiol. B 121: 3-11.
69. Rasmussen UB, Hesch RD. 1987. On antisense peptides: the parathyroid hormone as an experimental example and a critical theoretical view. Biochem. Biophys. Res. Commun. 149: 930-938.
70. Reinecke M, Collet C. 1998. The phylogeny of the insulin-like growth factors. Int. Rev. Cytol. 183: 1-94.
71. Ren Y, Blaker M, Seshadri L, McBride EW, Beinborn M, Kopin AS. 2003. Conserved cholecystokinin receptor transmembrane domain IV amino acids confer peptide affinity. J. Mol. Neurosci. 20: 115-124.
72. Richter G, Hein G, Blankenstein T, Diamantstein T. 1995. The rate interleukin 4 receptor: coevolution of ligand and receptor. Cytokin 7: 237-241.
73. Root-Bernstein RS. 1982a. Amino acid pairing. J. Theor. Biol. 94: 885-894.
74. Root-Bernstein RS. 1982b. On the origin of the genetic code. J. Theor. Biol. 94: 895-904.
75. Root-Bernstein RS. 1984. 'Molecular sandwiches' as a basis for the structural and functional similarities of interferons, MSH, ACTH, LHRH, myelin basic protein and albumins. FEBS Lett 168: 208-212.
76. Root-Bernstein RS. 1987. Catecholamines bind to enkephalins, morphiceptin and morphine. Brain Res. Bull. 18: 509-532.
77. Root-Bernstein RS. 2002. Molecular complementarity III. Peptide complementarity as a basis for peptide receptor evolution: a bioinformatic case study of insulin, glucagon and gastrin. J. Theor. Biol. 218: 71-84.
78. Root-Bernstein RS, Dillon PF. 1997. Molecular complementarity I. The complementarity theory of life and its origins. J. Theor. Biol. 188: 447-479.
79. Root-Bernstein RS, Dobbelstein C. 2001. Insulin binds to glucagon forming a complex that is hyper-antigenic and inducing complementary antibodies having an idiotype-antiidiotype relationship. Autoimmunity 33: 153-169.
80. Root-Bernstein RS, Holsworth DD. 1998. Antisense peptides: a critical mini-review. J. Theor. Biol. 190: 107-119.
81. Root-Bernstein RS, Westall FC. 1984. Serotonin binding sites I. Structures of sites on myelin basic protein, LHRH, MSH, ACTH, interferon, serum albumin, ovalbumin and red pigment concentrating hormone. Brain Res. Bull. 12: 425-436.
82. Root-Bernstein RS, Westall FC. 1986. Bovine pineal antireproductive tripeptide binds to luteinizing hormone-releasing hormone: a model for peptide modulation by sequence specific peptide interactions? Brain. Res. Bull. 17: 519-528.
83. Ruff MR, Martin BM, Ginns EI, Farrar WL, Pert CB. 1987. CD4 receptor binding peptides that block HIV infectivity cause human monocyte chemotaxis. Relationship to vasoactive intestinal polypeptide. FEBS Lett. 211: 17-22.
84. Ruiz-Opazo N, Akimoto K, Herrera VL. 1995. Identification of a novel dual angiotensin/vasopressin receptor on the basis of molecular recognition theory. Nat. Med. 1: 1074-1081.
85. Ruiz-Opazo N, Hirayama K, Akimoto K, Herrera VL. 1998. Molecular characterization of a dual endothelin-1/angiotensin II receptor. Mol. Med. 4: 96-108.
86. Sahagun-Ruiz A, Colla JS, Juhn J, Gao JL, Murphy PM, McDermott DH. 2001. Contrasting evolution of the human leukocyte N-formylpeptide receptor subtypes FPR and FPRL1R. Genes Immun. 2: 335-342.
87. Sautebin L, Rombola L, Di Rosa M, Caliendo G, Perissuitti E, Grieco P, Sseverino B, Santagada V. 2000. Synthesis and structure-activity of antisense peptides corresponding to the region for CaM-binding domain of the inducible nitric oxide synthase. Eur. J. Med. Chem. 35: 727-732.
88. Schenk JO, Morocco MT, Ziemba VA. 1991. Interactions between the argininyl moieties of neurotensin and the catechol protons of dopamine. J. Neurochem. 57: 1787-1795.
89. Schwabe C. 1990. New thoughts on the evolution of hormone-receptor systems. Comp Biochem. Physiol. A 97: 101-106.
90. Seed B. 1987. An LFA-3 cDNA encodes a phospholipid-linked membrane protein homologous to its receptor CD2. Nature 329: 840-842.
91. Siemion IZ, Stefanowicz P. 1992. Periodical changes of amino acid reactivity within the genetic code. Biosystems 27: 77-84.
92. Siemion IZ, Zbozien-Pacamaj R, Stefanowicz P. 2001. New hypothesis on amino acid complementarity and its evaluation on TGF-beta(2)-related peptides. J. Mol. Recognit. 14: 1-12.
93. Stefani M, Bucciantini M, Taddei N, Mincione G, Manao G, Ramponi G. 1994. Antisense peptides to the 43-57 region of acylphosphatase and to the 46-60 region of two isoenzymes of a low-M(r) phospotyrosine protein phospatase do not interact with the corresponding proteins. Biotechnol. Appl. Biochem. 20 (pt 2): 241-249.
94. Stein RA, Staros JV. 2000. Evolutionary analysis of the ErbB receptor and ligand families. J. Mol. Evol. 50: 397-412.
95. Swords BH, Carr DJ, Blalock HE, Berecek KH. 1990. An antibody directed against a peptided encoded by RNA complementary to mRNA for vasopressin recognizes putative vasopressin receptors. Neuroendocrinology 51: 487-492.
96. Takei Y. 2000. Structural and functional evolution of the natriuretic peptide system in vertebrates. Int. Rev. Cytol. 194: 1-66.
97. Takeuchi Y, Root-Bernstein RS, Shih JC. 1990. Peptide displacement of [3H] 5-hydroxytryptamine binding to cortical membranes. Brain Res. Bull. 25: 817-820.
98. Toh H, Ichikawa A, Narumiya S. 1995. Molecular evolution of receptors for eicosanoids. FEBS Lett. 361: 17-21.
99. Tropsha A, Kizer JS, Chaiken IM. 1992. Making sense from antisense: a review of experimental data and developing ideas on sense-antisense peptide recognition. J. Mol. Recognit. 5: 43-54.
100. Vaughn MK, Johnson LY, Blask DE, Brainard GC, Dinh DT, Petterborg LJ, Reiter RJ. 1980. Effect of synthetic threonylseryllysine (TSL), a proposed pineal peptide, on reproductive organ weights and plasma and pituitary levels of LH, FSH, and prolactin in intact and castrated immature and adult male rodents. Neuroendocr. Lett. 2: 235-240.
101. Van Kesteren RE, Tensen CP, Smit AB, van Minnen J, Kolakoski LF, Meyerhof W, Richter D, van Heerikhuizen H, Verugdenhil E, Geraerts WP. 1996. Co-evolution of ligand-receptor pairs in the vasopressin/oxytocin superfamily of bioactive peptides. J. Biol. Chem. 271: 3619-3626.
102. Walter R. 1975. Neurophysins: carriers of peptide hormones. Ann. NY Acad. Sci. 248 passim.
103. Weigent DA, Clarke BL, Blalock JE. 1994. Peptide design using a genetically patterned binary code: growth hormone-releasing hormone as a model. Immunomethods 5: 91-97.
104. Wijkhuisen A, Sagot MA, Frobert Y, Creminon C, Grassi J, Boquet D, Couraud JY. 1999. Identification in the NK1 tachykinin receptor of a domain involved in recognition of neurokinin A and peptide but not of substance P. FEBS Lett. 447: 155-159.
105. Wimalawansa SJ. 1997. Amylin, calcitonin gene-related peptide, calcitonin, and adrenomedullin: a peptide superfamily. Crit. Rev. Neurobiol. 11: 167-239.
106. Wu X, Richards NT, Johns EJ, Kohsaka T, Nakamura A, Okada H. 1997. Influence of ETR-p1/f1 antisense peptide on endothelin-induced constriction in rat renal arcuate arteries. Br. J. Pharma. 122: 316-320.
107. Yu B, Caspar DL. 1998. Structure of cubic insulin crystals in glucose solutions. Biophys. J. 74: 616-622.